Overview

Feminizing hormone therapy refers to the combination of estrogen (usually estradiol) and testosterone blockers (anti-androgens) given to males who identify as transgender women or as non-binary. The goal is to suppress the body's own testosterone and raise estrogen, producing typically female secondary sex characteristics — breast growth, softer skin, a more feminine fat distribution, and reduced body and facial hair.

The most common drugs are:

• Estradiol — the main female sex hormone, taken as pills, injections, patches or gel.
• Spironolactone — a diuretic that also blocks androgen receptors and lowers testosterone. It is the most widely used blocker in the United States.
• Cyproterone acetate (CPA) — a progestogen with strong anti-androgen effects, used in Europe and elsewhere.
• Bicalutamide — a non-steroidal anti-androgen that blocks the androgen receptor without lowering testosterone.
• GnRH agonists (e.g. leuprorelin/Lupron) — "puberty blockers" that shut down the testes' hormone production entirely.

This page describes what these drugs do to the male body, how much of it is reversible, the health risks, and how detransitioners describe the experience. It is not medical advice. If you are considering stopping or starting these drugs, speak to a doctor.

What the drugs do to the male body

The male body is built around testosterone. Suppressing it and adding estrogen changes far more than appearance. The table below summarises the expected effects and how reversible they are.

Sources for these timelines include Mayo Clinic, University of California, San Francisco (UCSF) Transgender Care, and Johns Hopkins Medicine.

Breast growth

Breast development is the clearest permanent effect. Small, often painful "breasts buds" typically appear within the first few weeks to months, and growth continues for two to five years. Most people develop an A or small B cup. Once breast tissue has formed, stopping hormones does not remove it — it may shrink slightly, but the glandular tissue remains. Many detransitioned men describe this as the change that most visibly marks them and that they most want reversed.

I have lumps of hard breast tissue under my nipples that haunt me every day and impede my confidence and intimacy. —MythicalDawn, detrans male.

The only problem I have left is my breast tissue... When you come off HRT what breast tissue you have will probably shrink a little, so depending on what size your chest is you might not have to do anything at all to feel 'normal' again. —Any_Requirement_9098, detrans male.

Genital and sexual changes

Testosterone drives male sexual function, so suppressing it has immediate effects: fewer spontaneous and morning erections, softer erections, reduced ejaculate volume, and lower libido. The testes typically shrink by 25–50%, and this atrophy can be permanent. Penile tissue can also lose size and elasticity when erections stop.

Recovery after stopping varies enormously. Some men regain function within months; others report problems years later.

It took a month or two for mine to function how it used to before transition... I have no balls but my dick works totally fine. —nndndbsbsuzb, detrans male.

My T has never returned to its pre-HRT levels, and I've been having consistent issues with erectile dysfunction that only started while I was on estradiol — it seems that my testes have just never recovered their old capacity... for me its been about 3 years now and stuff hasn't gone back to normal on its own. —MythicalDawn, detrans male.

I'm 24 too, the breast tissue is there but not to the degree anyone really notices but, for me the sexual side effects of estrogen have never gone away, still have ED and testicular atrophy almost 5 years after stopping. —MythicalDawn, detrans male.

Fertility

Fertility is one of the least predictable outcomes. Testosterone suppression stops sperm production in most men, sometimes within weeks. Some men recover sperm production after stopping; others do not. The Mayo Clinic notes that "the risk of permanent infertility increases with long-term use of hormones," and that even after stopping, "the testicles might not recover enough to ensure conception without infertility treatment." UCSF Transgender Care advises patients to "assume that within a few months of starting hormone therapy you could permanently and irreversibly lose the ability to create sperm."

Detransitioners describe confronting this loss directly.

Stopping estrogen and beginning detransition brought me face to face with the reality, as result of my actions, that I will never be able to have my own children and that was quite depressing and I felt great shame for what I'd done to my body. —Patient-Candle-4949, detrans male.

Others have recovered fertility, though the timeline is long and uncertain.

everything else has gone back to normal — I am unavoidably aware of the fact that my testes are making testosterone again. I am fertile again. —Vedeneres, detrans male.

Known risks

Beyond the intended feminizing changes, these drugs carry real medical risks. Some are well documented in large cohort studies; others rest on drug labels, studies of other populations (postmenopausal women, men treated for prostate cancer) or case reports. The table below brings together every risk with published evidence, then the sections that follow go into detail. "Permanent?" refers to whether the harm can outlast the drugs, not whether the drug's effect stops when it is stopped.

What the estradiol label warns

Estradiol products sold in the United States have carried the FDA's strongest warning, a boxed warning, since 2003. It lists stroke, deep vein thrombosis, pulmonary embolism, heart attack, invasive breast cancer and probable dementia (FDA estradiol label). These warnings come from the Women's Health Initiative, a trial in postmenopausal women taking estrogen at replacement doses. In late 2025 the FDA announced it would remove the cardiovascular, breast cancer and dementia language from menopause hormone labels (The 19th 2025).

Neither the warning nor its removal tells us much about males. Feminizing regimens often use estradiol at higher doses than menopause therapy, given to a body with no history of exposure to female hormone levels. The cohort studies of trans women summarised above, not the menopause data, are the closest evidence, and they show higher clot and stroke rates than in either sex.

Blood clots and cardiovascular risk

Estrogen increases the risk of venous thromboembolism (blood clots) and stroke, especially when taken orally, because oral estradiol passes through the liver and raises clotting factors. A large study using records from Kaiser Permanente, a large US health system (Getahun et al., reported by the funder, the Patient-Centered Outcomes Research Institute) found that transfeminine people taking oral estrogen had roughly double the rate of blood clots and stroke compared to non-transgender men and women. Injectable and transdermal estrogen carried lower clot risk than pills, though stroke risk remained elevated. The largest European study points the same way. In a Dutch cohort of 2,517 trans women followed for about nine years, clots occurred 4.5 times as often as in men and stroke 1.8 times as often (Nota et al. 2019). In the US cohort, the risk of ischaemic stroke grew with time on estrogen, reaching roughly ten times that of men after six years (Getahun et al. 2018). A 2024 meta-analysis that pooled 22 studies found smaller excesses compared with men (stroke 1.3 times, clots 1.4 times), which shows how uncertain the exact size of the risk still is (EJE meta-analysis 2024).

Spironolactone-specific risks

Spironolactone is a potassium-sparing diuretic, and its risks are distinct from estrogen's:

• Hyperkalemia — dangerously high potassium, which can cause cardiac arrhythmias and, rarely, be fatal.
• Kidney stress and impaired function — the drug acts on the kidneys and can worsen existing kidney problems.
• Low blood pressure, dizziness, and dehydration — many users report frequent urination, thirst, and lightheadedness.
• Fatigue and brain fog — commonly reported, especially at the high doses (100–200 mg/day) used in feminizing therapy.

Brain tumour risk: cyproterone acetate

Meningiomas are the most common type of brain tumour. They are usually benign — meaning they do not spread like a cancer — but they can grow large enough to press on the brain, causing headaches, vision loss, seizures, personality changes, and in severe cases requiring surgery. Many meningiomas carry progesterone receptors, which means progestogens (synthetic progesterone-like drugs) can fuel their growth.

Cyproterone acetate (CPA) is a powerful progestogen and anti-androgen widely used in feminizing hormone regimens outside the United States. It is the anti-androgen most clearly linked to meningioma risk, and the evidence is strong:

• A large French national cohort study of over 250,000 women (Weill et al. 2021) found a strong dose-dependent relationship between CPA and meningioma requiring surgery or radiotherapy. The risk was roughly 7-fold higher at cumulative doses above 12 g, rising to over 20-fold at cumulative doses above 60 g. After stopping CPA for one year, the risk dropped noticeably but did not fully return to baseline.
• A Danish population-wide study (Mikkelsen et al. 2021) confirmed the dose-response pattern: cumulative doses above 10 g were associated with a 19-fold increased risk of meningioma compared to non-users. Even past users who had stopped still carried a roughly 5-fold elevated risk one year after their last prescription.
• A Dutch cohort study (Nota et al. 2018) found meningioma rates roughly 4 times higher than expected in trans women — all of whom were taking CPA.
• A 2023 systematic review of 12 case reports of trans women developing meningiomas on CPA (Millward et al. 2023) found that most were taking 50–100 mg/day — historically common doses in feminizing regimens — for a median of 9.5 years. Multiple meningiomas were common. The review concluded that risk increases at doses above 25 mg/day.

The risk is not limited to very high doses. A 2024 case report described a trans woman who developed a giant meningioma after only 5 years on ≤25 mg/day CPA (Bouillon et al. 2024). The dose below which CPA is safe remains unknown.

The European Medicines Agency has recommended restricting CPA use to doses no higher than 10 mg/day where possible. In practice, many feminizing regimens still use 25–50 mg/day, and some older patients were maintained on 100 mg/day or more for years.

Spironolactone, by contrast, has not been associated with meningioma risk in human studies. A 2025 population-based cohort study (Martin et al. 2025) found no association despite spironolactone's progesterone receptor affinity, and a large French case-control study of 18,061 meningioma patients (Roland et al. 2024) found no excess risk (odds ratio 0.95, 95% confidence interval 0.84–1.09). The FDA tumour warning on spironolactone is based on rat studies at doses up to 150 times the human dose, and the International Agency for Research on Cancer classifies it as Group 3 — not classifiable as carcinogenic to humans (Mackenzie et al. 2017). If brain tumour risk is your concern, the drug to scrutinise is CPA, not spironolactone.

Detransitioners' complaints about spironolactone tend to focus on cognition and energy rather than cancer:

Spironolactone + estrogen essentially made me a retard, especially in the beginning and severely impacted my performance at work. —Beautifulsexybabe, detrans male.

You're definitely on to something when you mentioned neurobiology. I feel like the spironolactone really effed up something in my brain, the androgen receptors… SOMETHING. It's not all in your head. —Beautifulsexybabe, detrans male.

One /r/detrans commenter with a verified pharmacist flair put the cancer question in proportion:

On the cancer part, you actually might be on to something. It hasn't been linked to cancer in humans, but it has in animal models. So, that's always something to consider. Most folks aren't aware. The general medical consensus is, "don't use it unless you need it." —AssignedSnail, verified pharmacist ✅.

Detransitioners frequently single out spironolactone as the drug that made them feel worst.

all HRT did was make me almost manic: extremely clingy, whiny, insecure. None of it felt right mentally, especially spiro with the terrible headaches even on low doses. —KotoriMinami21, questioning own gender transition.

Taking spiro + finasteride gave me all kinds of side effects. I would feel dizzy and lethargic on a daily basis... Day in and day out like a total zombie with no energy whatsoever. —Vanilla-One, detrans male.

Other risks

• Liver effects — cyproterone can cause dose-related hepatitis and, rarely, liver failure; its labelling requires liver tests before and during treatment (Androcur SmPC). Bicalutamide was long avoided because of liver-toxicity concerns, and oral estrogen is processed by the liver.
• Prolactin — estrogen, especially combined with cyproterone, raises prolactin. Very high levels can come from a pituitary tumour (prolactinoma), which can cause headaches and vision problems (Wilson et al. 2020).
• Gallstones — estrogen increases cholesterol in bile and slows bile flow; the Endocrine Society lists cholelithiasis as a moderate risk (Hembree et al. 2017).
• Bone density — low sex-hormone states reduce bone mineral accrual, particularly if hormones are started young, if puberty was blocked, or if hormones are stopped after gonadectomy (Giacomelli & Meriggiola 2022).
• Metabolic changes — loss of muscle, more body fat, lower insulin sensitivity and higher triglycerides (Shadid et al. 2020).
• Muscle and pelvic floor weakening — long-term testosterone suppression can reduce pelvic floor and penile muscle tone.
• Cancer risk — breast tissue growth increases breast cancer risk relative to males, though absolute risk remains below that of females (de Blok et al. 2019). The long-term cancer risk in males on feminizing hormones is not well established.

What detransitioners report

Clinical sources describe most of these effects as "usually reversible." The detransitioned men on /r/detrans who post about lasting harm describe something else. Their accounts are self-selected and cannot tell us how common these outcomes are, since men who recovered fully are less likely to keep posting. But they show the range of what can happen, and several describe harm after very short exposure, which no study has examined.

Sexual function. The most frequent complaint is sexual function that did not come back.

My sexuality was completely annihilated in 2017 when I took spironolactone, finasteride and estrogen for the first time ever. In a matter of 2-3 days, has never returned since. No libido, no pleasurable orgasms, looking at naked people is like looking at a wall, stuck in an asexual state. I regret doing taking those drugs everyday. —Beautifulsexybabe, detrans male

There are many stories of guys here who only took a single dose, and their erections are weaker and unsatisfying for the rest of their life. Same thing with ejaculate volume… I was also left with permanently cold genitals, that are uncomfortable and much colder than they used to be. I took two doses of estrogen, and my last dose was over 9 months ago. —split_skunk, detrans male

My function is basically how a venous leak sounds on paper, it’s as though whatever blood gets into my penis just drains right back out again… My testicular atrophy has also never recovered, another reason I’m getting on Clomid because they are at present quite literally child-sized, I just hope I’m not too late to restore function somewhere. —MythicalDawn, detrans male

One man who used GnRH-agonist injections as his blocker found that recovery got harder with each cycle:

Every time my libido and function came back after roughly two months, but after the last injection I took (decided to stop transitioning one week later) it was like something got broken. It’s been seven months since then and my libido and function is almost completely dead —christa-paffgen, detrans male

Breasts and pain. Men describe breast growth as fast, permanent and sometimes painful for years.

The harmful side effects are largely unknown due to lack of interest in doing clinical trials to study them. I was left with permanent breast pain. That was not in any of the warnings or medical literature. No one knows what to do with me now. I'm basically the result of a medical experiment I didn't know was an experiment when I participated. —UniquelyDefined, detrans male

Whole-body health. Others list problems that go well beyond appearance.

During the 15 months I was on HRT (estrogen & spironolactone) the health issues I experienced were severe back and joint pain, total loss of energy, fatigue, brain fog, depression, frequent migraines, and rapid weight gain. —Hot_Strawberry_166, detrans male

I've experienced several life-changing ailments due to anti-androgens an estrogen. Erectile dysfunction is only the tip of the iceberg. —ValidVanity, detrans male

I was on the same medications and something called Lupron which is the puberty blocker that is literal poison. All for nearly two years. My symptoms are fatigue, headaches, brain fog/memory loss, dysautonomia, hearing and vision loss too. —Tawayy13, detrans male

A man who has taken cross-sex hormones for three decades describes what long-term use has meant for him:

I began taking cross sex hormones by age 25 and have done that for over 30 years at this point. I have a number of health issues from doing that. Osteoporosis is a major problem and I am in pain daily from it. —Liminal_exp, Socially Trans - Regrets entire Transition

The mind. Brain fog is one of the most consistent themes. One man said it nearly cost him his education:

Physical effects aside(it ruined my health), just the sheer brainfog alone caused me to fail several classes and almost having to drop out. Of course there's extreme mood swings too, which were mostly negative —def0_not_an_alt, detrans male

Hrt gave me mental issues similar to someone with borderline personality, unknown long term health side effects, don't want breast development anymore, my penis was very painful when aroused and I got beyond tired of not having a sex drive —Dear-Shift-7636, detrans male

Taken together, these accounts point to a gap between how the drugs are presented and how some men experience them. Online and in some clinics, feminizing hormones are described as gentle and largely reversible. These men describe drugs that changed their bodies quickly, in ways they could not control, with effects that outlasted the prescription. For what happens after stopping, see estrogen cessation. For harms caused by treatment more broadly, see iatrogenic harm.

Mental and cognitive effects

Many males report emotional changes on feminizing hormones — some describe greater access to crying or a wider emotional range, while others describe brain fog, poor concentration, mood instability, or worsening anxiety and depression. The evidence on mental health effects is genuinely mixed and of low certainty. A 2025 systematic review by Miroshnychenko et al. 2025 found the evidence for effects of gender-affirming hormone therapy on depression, gender dysphoria, and global function to be very low certainty, concluding that "we cannot exclude the possibility of benefit or harm."

A Finnish register study (Ruuska et al. 2026) found that psychiatric morbidity among gender-referred adolescents actually increased during follow-up after medical gender reassignment — rising from about 10% to 61% in the feminizing group — though the study cannot establish causation and the population had high baseline psychiatric needs.

Detransitioners describe a range of mental effects.

HRT made me feel 'sick' in a sense that I had constant brainfog, executive dysfunction, feeling weak, lack of motivation... Back on T my energy and motivation came back and I'm feeling almost like new born. —magiruuvelvet, detrans male.

The hormonal imbalance made me try to commit suicide twice. After stopping HRT and detransitioning my mental health and clarity has improved a ton. I'm so much happier on testosterone and full of energy! —WallaWallaby011, detrans male.

Surprisingly, estrogen had no impact at all on my mental state. If I couldn't see the physical changes, I wouldn't even know if I was taking it... It did however unlock the ability to cry. —Your_socks, detrans male.

Note the disagreement. Hormones affect people differently, and the confident claims made online — that estrogen will make you calmer, happier, or "more yourself" — are not reliably supported by evidence.

Reversibility: what comes back and what does not

When a male stops estrogen and testosterone blockers, testosterone production usually resumes on its own, though the timeline varies from weeks to years and depends on how long the drugs were taken and at what age. Recovery is generally better for those who were on hormones for shorter periods and who started after completing male puberty.

Usually reversible: muscle mass and strength, fat distribution, skin texture, body and facial hair growth, libido, mood.

Often slow or incomplete: erectile function, ejaculate volume, testicular size, sperm production, testosterone levels.

Usually permanent: breast tissue, and any skeletal changes that occurred if hormones were started before or during male puberty (such as reduced height or widened hips).

Recovery is not guaranteed, and some men report persistent problems years after stopping.

I was on blockers for around 3 years prior to HRT. I hoped my T levels would naturally go up a bit once I was off E. But it's been six months and physically nothing happened... I'm not sure if my body needs more time, or if my T levels are nuked forever. —throwaway_5267, detrans male.

I was on a very high dose of HRT for two weeks... I've been off for three months... It's harder to get hard in general... My doctors say it may take up to a couple years to recover, or that I may never fully recover. —split_skunk, detrans male.

Others recover well.

I was on injectable E for a year, AA's for 4, and oral E for 3 and my sperm function and erections and muscle all came back. —BrilliantSweaty2729, detrans male.

The informed consent gap

A recurring theme in detransitioners' accounts is that consent was not truly informed — that risks were minimised, alternatives were not discussed, and the permanence of changes was understated. In a 2021 survey of 100 detransitioners, Littman 2021 found that 55% felt their initial evaluation was inadequate and that nearly half said counselling was overly positive about benefits while downplaying risks.

I just hate that these doctors allowed me to do this to myself in a 2 hour appointment. I will never be the same person again... And this was only 18 days. —Mundane-Search9868, detrans male.

No one's consent is informed. Because we don't know everything that hormones do to people over the long run. And what we do know is not good. —butchpeace725, detrans female.

My endo gave me a pamphlet of the aesthetic changes that would happen, and some of the health concerns... and admitted that they didn't know the full health consequences that comes with giving a female testosterone. —watching_snowman, Socially Trans — Regrets entire Transition.

The Cass Review 2024, England's independent review of youth gender services, found the evidence base for feminising hormones to be weak and called for fertility counselling and preservation to be offered before any treatment begins. The truth is that long-term data on males taking feminizing hormones is sparse, and much of what is claimed about safety and reversibility rests on low-certainty evidence.

Questions worth asking

If you are a male considering, currently taking, or coming off these drugs, some questions that detransitioners and clinicians raise:

• What changes are permanent, and am I prepared to live with them if my feelings change?
• Have I banked sperm, and do I understand the fertility risks?
• What are the specific risks of the drug I've been prescribed (spironolactone, cyproterone, bicalutamide)?
• Have I been properly assessed for other causes of distress — trauma, depression, OCD, autism, internalised homophobia?
• Do I have a plan and medical support if I decide to stop?
• What is my support system if my feelings about transition change?

See also

• Puberty blockers — what GnRH agonists do to adolescents.
• Gender dysphoria — what the diagnosis means and how it is contested.
• Detransition — why people reverse transitions.
• Support directory — gender-exploratory therapy and detrans support groups.

References

• Weill, A. et al. (2021). Use of high dose cyproterone acetate and risk of intracranial meningioma in women: population based cohort study. source.
• Mikkelsen, S. H. et al. (2021). Use of cyproterone acetate and risk of meningioma: a Danish nationwide population-based cohort study. source.
• Millward, K. et al. (2023). Development and Growth of Intracranial Meningiomas in Transgender Women Taking Cyproterone Acetate as Gender-Affirming Progestogen Therapy: A Systematic Review. source.
• Martin, A. et al. (2025). Despite progesterone receptor affinity, spironolactone is not associated with meningioma development: A population-based cohort study. source.
• Roland, N. et al. (2024). Use of progestogens and the risk of intracranial meningioma: national case-control study. source.
• Mackenzie, I. S. et al. (2017). Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. source.
• Nota, N. M. et al. (2018). The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. source.
• Bouillon, C. et al. (2024). Giant Intracranial Meningiomas Requiring Surgery in 2 Transgender Women Treated With Cyproterone Acetate. source.
• Miroshnychenko, A. et al. (2025). Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. study page, source.
• Miroshnychenko, A. et al. (2025). Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis. study page, source.
• Littman, L. (2021). Individuals Treated for Gender Dysphoria with Medical and/or Surgical Transition Who Subsequently Detransitioned: A Survey of 100 Detransitioners. study page, source.
• Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
• Ruuska, S. et al. (2026). Psychiatric Morbidity Among Adolescents and Young Adults Who Contacted Specialised Gender Identity Services in Finland in 1996–2019: A Register Study. study page, source.
• Getahun, D. et al. (2018). Stroke and Blood Clot Risk in Transgender Women Taking Hormones. PCORI.
• Mayo Clinic. Feminizing hormone therapy. source.
• UCSF Transgender Care. Information on Estrogen Hormone Therapy. source.
• Johns Hopkins Medicine. Gender-Affirming Hormone Therapy (GAHT). source.
• Nota, N. M. et al. (2019). Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy: Results From a Large Cohort Study. Circulation 139(11). source.
• Getahun, D. et al. (2018). Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Annals of Internal Medicine 169(4):205–213. Stroke figures as summarised in Transgender patients and the role of the coagulation clinician, Journal of Thrombosis and Haemostasis.
• European Journal of Endocrinology (2024). Cardiovascular disease in transgender people: a systematic review and meta-analysis. source.
• de Blok, C. J. M. et al. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 365:l1652. source.
• Hembree, W. C. et al. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. JCEM 102(11):3869–3903. source.
• US Food and Drug Administration. Evamist (estradiol transdermal spray) prescribing information, boxed warning (revised 12/2023). source.
• The 19th (2025). FDA is changing black box warning on estrogen treatments. Here's why. source.
• European Medicines Agency (2020). Restrictions in use of cyproterone due to meningioma risk. EMA/147755/2020. source.
• Wilson, L. M. et al. (2020). Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review. International Journal of Transgender Health. source.
• Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment (2020). Endocrine. source.
• Androcur 50 mg tablets. Summary of Product Characteristics. electronic medicines compendium (UK). source.
• Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study (2024). medRxiv preprint. source.
• The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone (2022). Journal of the Endocrine Society 6(11):bvac133. source.
• Gupta, P. et al. (2022). Potassium Concentrations in Transgender Women Using Spironolactone: A Retrospective Chart Review. Endocrine Practice. source.
• Wiepjes, C. M. et al. (2019). Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen. Journal of Bone and Mineral Research 34(3):447–454. source.
• Dobrolińska, M. et al. (2019). Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. Journal of Sexual Medicine. source.
• Giacomelli, G. & Meriggiola, M. C. (2022). Bone health in transgender people: a narrative review. Therapeutic Advances in Endocrinology and Metabolism. source.
• Shadid, S. et al. (2020). Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. Diabetes Care 43(2):411–417. source.
• Incidence of Type 2 Diabetes Mellitus in Transgender Individuals Undergoing Gender Affirming Hormonal Therapy: A Systematic Review (2024). source.
• Menopausal hormone therapy increases the risk of gallstones: Health Insurance Database in South Korea (HISK)-based cohort study (2023). source.
• GenderGP. Cyproterone Acetate (CPA): Uses, Dosage & Side Effects. source.
• Androgen deprivation therapy and side effects: are GnRH antagonists safer? (2021). Asian Journal of Andrology 23(1). source.
• Guise, T. A. et al. (2007). Estrogenic Side Effects of Androgen Deprivation Therapy. Reviews in Urology 9(4):163–180. source.